completed

REMEDY was the first large, multi-country registry and cohort study of thousands of people with rheumatic heart disease (RHD) across much of Africa, the Middle East, and East Asia.

The objective of the REMEDY study was to:

  • Document clinical and echocardiographic characteristics of patients at presentation and;
  • Document disease progression and treatment practices over a two-year follow-up with particular reference to adherence to secondary prophylaxis and oral anticoagulation regimens.

Professor G. Karthikeyan, India

Another Co-Principal Investigator on the REMEDY study was Ganesan Karthikeyan, Professor, Cardiology, All India Institute of Medical Sciences.

Study Type

Observational - Registry

Study Design

Registry

NO. of Countries

14

NO. of Sites

25

NO. of Participants

3343

Study Period

2010-2016

Sponsor

PHRI

Canadian Institutes of Health Research (CIHR)

South African Medical Research Council

Ganesan Karthikeyan on Rheumatic Heart Disease (RHD) at the PHRI 20th anniversary symposium, 2019

Back To Top